The essential role of CDKs in promoting cell cycle progression (through phosphorylation of Retinoblastoma (Rb)) established CDK4/6Is as a selective target therapy to influence outcomes in breast cancer, especially therapy-resistant breast cancer [1]. This evidence concerns the gene CDK4 and breast cancer.